GGrantIndex
← Search

Cancer Center Administration

$179,629P30FY2023CANIH

Beckman Research Institute/City Of Hope, Duarte CA

Investigators

Linked publications, trials & patents

Trial NCT07664670Trial NCT07664579Trial NCT07650656Trial NCT07628894Trial NCT07619599Trial NCT07612085Trial NCT07611370Trial NCT07608627Trial NCT07608458Trial NCT07608445Trial NCT07595874Trial NCT07590583Trial NCT07583810Trial NCT07583303Trial NCT07582172Trial NCT07582159Trial NCT07578077Trial NCT07578025Trial NCT07544992Trial NCT07365306Trial NCT07363408Trial NCT07293403Trial NCT07288034Trial NCT07278856Trial NCT07275216Trial NCT07271355Trial NCT07235501Trial NCT07226544Trial NCT07226102Trial NCT07225855Trial NCT07225738Trial NCT07220447Trial NCT07219147Trial NCT07218913Trial NCT07218718Trial NCT07218692Trial NCT07218510Trial NCT07210086Trial NCT07202247Trial NCT07184294Trial NCT07136493Trial NCT07133997Trial NCT07128680Trial NCT07126301Trial NCT07125729Trial NCT07042438Trial NCT07040982Trial NCT07037004Trial NCT07025564Trial NCT07025538Trial NCT07020533Trial NCT07003100Trial NCT06996119Trial NCT06985784Trial NCT06954831Trial NCT06922604Trial NCT06918431Trial NCT06910761Trial NCT06860815Trial NCT06859008Trial NCT06834126Trial NCT06815029Trial NCT06815003Trial NCT06780787Trial NCT06763341Trial NCT06763328Trial NCT06735690Trial NCT06735664Trial NCT06731894Trial NCT06675136Trial NCT06675123Trial NCT06672224Trial NCT06626256Trial NCT06625619Trial NCT06581211Trial NCT06580015Trial NCT06575725Trial NCT06575686Trial NCT06575296Trial NCT06572631Trial NCT06572618Trial NCT06572605Trial NCT06549478Trial NCT06543381Trial NCT06538389Trial NCT06500377Trial NCT06498973Trial NCT06454409Trial NCT06454383Trial NCT06453044Trial NCT06447987Trial NCT06440850Trial NCT06408220Trial NCT06399419Trial NCT06328621Trial NCT06287944Trial NCT06260033Trial NCT06249282Trial NCT06196008Trial NCT06195891

Abstract

Abstract Cancer Center Administration The City of Hope Comprehensive Cancer Center (COHCCC) Administration provides effective and efficient administrative support to facilitate COHCCC strategic and operational priorities. During the current funding cycle, Administration was re-organized to strategically enhance its support of COHCCC priorities and address review critiques. A now fully integrated and realigned Administration is led by an experienced Associate Director for Administration (ADA), Ms. Ashley Baker Lee. Administration has expanded and now includes four additional senior managers to better facilitate the basic, clinical, translational, and population-based research and education mission of the COHCCC. Through this integration and expansion, the role that Administration now plays has grown considerably to ensure COHCCC and Cancer Center Support Grant (CCSG) needs are represented, prioritized, and aligned in an effective manner Administration facilitates COHCCC strategic priorities, oversees all COHCCC programmatic activities, and promotes collaborative multidisciplinary and transdisciplinary translational research by integrating basic, translational, population-based, and clinical research as well as training activities across the COHCCC. Administration is also responsible for coordinating all COHCCC research administrative and strategic functions in pursuit of COHCCC’s mission. Administration ensures COHCCC adherence to all CCSG expectations and guidelines from proposal stage through reporting. Administration supports key COHCCC functions such as space management, Shared Resources business support, financial management, faculty recruitment/retention, meeting/seminar facilitation, pilot program management, membership activities, connections to central offices, communications, and strategic planning/evaluation support. Evidence of impact of Administration includes successful recruitment and onboarding of 48 new COHCCC Program Members; development and endorsement of a new COHCCC strategic plan; expansion of laboratory research space through purchase/renovation of a 141,000 sq. ft. building; and implementation of multiple IT systems in support of research, including Epic and OnCore.

View original record on NIH RePORTER →